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Abstract. Plasmodium falciparum and P. malariae occur endemically in many parts of Africa. Observations from
malariotherapy patients suggest that co-infection with P. malariae may increase P. falciparum gametocyte production.
We determined P. falciparum gametocyte prevalence and density by quantitative nucleic acid sequence-based amplifi-
cation (QT-NASBA) after antimalarial treatment of Kenyan children with either P. falciparum mono-infection or P.
falciparum and P. malariae mixed infection. In addition, we analyzed the relationship between mixed species infections
and microscopic P. falciparum gametocyte prevalence in three datasets from previously published studies. In Kenyan
children, QT-NASBA gametocyte density was increased in mixed species infections (P 0.03). We also observed higher
microscopic prevalences of P. falciparum gametocytes in mixed species infections in studies from Tanzania and Kenya
(odds ratio 2.15, 95% confidence interval 0.99–4.65 and 2.39, 1.58–3.63) but not in a study from Nigeria. These data
suggest that co-infection with P. malariae is correlated with increased P. falciparum gametocytemia.
INTRODUCTION
Plasmodium falciparum and P. malariae are malaria species
that occur endemically in many parts of sub Saharan Africa.
Mixed infections with both species are usually observed in a
small proportion of persons in cross-sectional studies (2–
14%),1–4 although their cumulative prevalence has been
documented at 20–50% in longitudinal studies conducted
over 1–2 years.2–4 The co-occurrence of P. falciparum and P.
malariae is often higher than would be expected on the basis
of their individual parasite prevalence,5–8 and one parasite
species may influence the infection dynamics of the other.
The biologic and subsequent clinical interactions are there-
fore of interest, especially in light of vaccination trials specifi-
cally targeted at P. falciparum.
In mixed infections, the presence of P. malariae parasites
can influence the disease manifestation of P. falciparum with
a reduction in disease severity9 and a lower peak parasit-
emia,10 possibly as a consequence of heterologous immu-
nity.11,12 Observations from malariotherapy patients indicate
that co-infection with P. malariae may increase P. falciparum
gametocytemia.13 If this increased gametocyte production is
manifested in co-infections in field settings, this could have
implications for the spread of malaria and malaria control.
Predictably few field studies have addressed this issue: most
clinical studies focus on P. falciparum mono-infections and
use co-infection with other malaria species as an exclusion
criterion. A study of 5,682 symptomatic patients in Thailand
found that P. falciparum gametocytes were less common in
mixed infections with P. vivax.14 A small cross-sectional study
in 25 households in Mozambique suggested that P. falciparum
gametocytes may also be less common in the presence of P.
malariae.1 We examined the relation between P. falciparum
gametocytemia and mixed infection with P. malariae in four
separate studies. We compare P. falciparum gametocyte
prevalence and density assessed by molecular methods after
anti-malarial treatment of Kenyan children naturally infected
with either P. falciparum mono-infection or P. falciparum and
P. malariae mixed infection. In addition, we present analyses
of the relationship between mixed species infections and mi-
croscopic P. falciparum gametocyte prevalence in three large
datasets from previously published studies conducted in Tan-
zania, Kenya, and Nigeria.
MATERIALS AND METHODS
Gametocytemia and mixed species infections after antima-
larial drug treatment. The study assessing P. falciparum ga-
metocyte prevalence and density after antimalarial treatment
was conducted from October to December 2004 in Mbita, a
rural village on the shores of Lake Victoria in the Suba Dis-
trict of western Kenya. Transmission intensity is high and
perennial in the study area (entomologic inoculation rate ap-
proximately six infectious bites per person per month)15 with
P. falciparum as predominant parasite species accounting for
more than 95% of the clinical malaria cases.16 Patients with P.
falciparum mono-infection were enrolled as part of a larger
drug sensitivity study that was reported previously (Clinical
Trials registration no. ISRCTN31291803 available from http://
www.controlled-trials.com/ISRCTN31291803).17 Children 6
months to 10 years of age with a temperature > 37.5C° mea-
sured by earthermometer or a history of fever within the last
48 hours and with P. falciparum mono-infection at a density
between 500 and 100,000 parasites/L were eligible for re-
cruitment. Exclusion criteria were inability to take drugs
orally, known hypersensitivity to any of the drugs given, re-
ported treatment with antimalarial chemotherapy in the past
two weeks, evidence of chronic disease or acute infection
other than malaria, and domicile outside the study area and
signs of severe malaria. Children with P. falciparum and P.
malariae mixed infection were enrolled in the study on the
basis of the same criteria but no minimum parasite density
was used as an inclusion criterion. All subjects included in the
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analyses were treated with sulfadoxine-pyrimethamine (SP;
Fansidar; Hoffmann LaRoche, Basel, Switzerland) plus
amodiaquine (AQ), 10 mg/kg, once a day for three days
(Camoquine; Pfizer, Dakar, Senegal) and subsequently fol-
lowed for 28 days. The study protocol (SSC no. 791) was
reviewed and approved by the Scientific Steering Committee
and Ethical Review Committee of the Kenya Medical Re-
search Institute, Nairobi, Kenya.
Microscopy and molecular parasite detection. Giemsa-
stained blood smears were screened for asexual parasites and
gametocytes at enrollment and on days 3, 7, 14, and 28 after
treatment. Slides were declared negative if no parasites were
observed in 100 microscopic fields, each containing approxi-
mately 15–20 leukocytes; asexual parasites and gametocytes
were counted against 200 and 500 leukocytes, respectively.
Conversion to parasites/microliter was made using a conver-
sion rate of 8,000 leukocytes/L. Parasite detection by quan-
titative nucleic acid sequence-based amplification (QT-
NASBA) was done for a random selection of P. falciparum
mono-infections with complete follow-up (47 of 127)17 and
for all P. falciparum plus P. malariae mixed infections (21 of
21). Nucleic acids were extracted from 50-L finger prick
blood samples by the method described by Boom and oth-
ers.18 Plasmodium falciparum QT-NASBA was performed on
a NucliSens EasyQ analyzer (bioMérieux, Boxtel, The Neth-
erlands) as described elsewhere for Pfs25 mRNA.19 Pfs25
mRNA is only expressed in stage V P. falciparum gameto-
cytes,20 and the Pfs25 QT-NASBA has a detection limit of
20–100 gametocytes/mL. Nuclisens Basic kits (bioMérieux)
were used for amplification according to the manufacturer’s
instructions at a KCl concentration of 80 mM. A standard
dilution series of in vitro cultured mature NF54 gametocytes21
was included in each run to ascertain gametocyte density. The
presence of P. malariae parasites in mixed infections was con-
firmed by detecting P. malariae-specific 18S ribosomal RNA
using QT-NASBA.22
Data analyses. Nonparametric Wilcoxon rank sum tests
were used to test differences between groups for statistical
significance in case of continuous variables; chi-square tests
were used for dichotomous variables. Multiple logistic regres-
sion models with generalized estimating equations (GEEs)
were used to test the influence of P. falciparum plus P. ma-
lariae mixed infection on Pfs25 QT-NASBA gametocyte
prevalence. A similar procedure was carried out using GEEs
for Pfs25 QT-NASBA gametocyte density. Estimates were
adjusted for potential confounding factors (i.e., age, treat-
ment outcome, microscopic asexual parasite density at enroll-
ment, and fever at enrollment) and a random effect was in-
cluded in the models to show correlations within persons. To
quantify the influence of co-infection with P. malariae on P.
falciparum gametocyte densities during follow-up, we deter-
mined the area under the curve (AUC) of Pfs25 QT-NASBA
gametocyte density versus time.23,24 This measure incorpo-
rates both the magnitude and the duration of transmission
potential and was described by Mendez and others.24 The
AUC from days 0 to 42 was calculated as AUC  [(3 − 0) ×
(g0 + g3)/2 + (7 − 3) × (g3 + g7)/2 + (14 − 7) × (g7 + g14)/2 +
(28 − 14) × (g14 + g28)/2]/28 where gd represents Pfs25 QT-
NASBA gametocyte density on day d. Gametocyte negative
samples were included as zeroes. The measure was scaled by
28 so that it represents AUC per day and this was trans-
formed by log10 for comparisons. Statistical analyses were
performed using procedures available in SPSS version 12.0
(SPSS Inc., Chicago, IL) and Stata version 8.0 (Stata Corpo-
ration, College Station, TX).
Analyses on data from three previously conducted stud-
ies. Data from three studies were analyzed on the basis of the
availability of information on the prevalence of P. falciparum
asexual parasites and gametocytes and P. malariae asexual
parasites.
The first dataset was obtained from a series of cross-
sectional studies in six altitude transects (150–1,800 meters) in
the Kilimanjaro and Tanga regions in northern Tanzania.25
Cross-sectional surveys in individuals 6 months to 45 years of
age were conducted twice in a period of 6 months; 100 mi-
croscopic fields were screened for asexual parasites of P. fal-
ciparum and P. malariae and gametocytes of P. falciparum.
Asexual and gametocyte densities were recorded per 200 leu-
kocytes and 500 leukocytes, respectively.
The second dataset was obtained from a longitudinal study
in Mbita in western Kenya.26 Children 6 months to 16 years of
age were screened weekly for five weeks; 100 microscopic
fields were screened for asexual parasites of P. falciparum
and P. malariae and gametocytes of P. falciparum.
The third dataset was obtained from the Garki dataset from
1970 and 1971, the years prior to the transmission-reducing
intervention (http://www.sti.ch/research/biostatistics/
downloads.html).27 In this part of the study, surveys were
conducted in the general population (0–72 years of age) of
villages in Garki in northern Nigeria. Every ten weeks slides
were collected and 200 or 400 microscopic fields were
screened for asexual parasites of P. falciparum and P. ma-
lariae and gametocytes of P. falciparum. Parasite densities
were calculated as the percentage of positive fields. Sampling
took place every 10 weeks.
Microscopic gametocyte density data were available for the
Kenyan and Tanzanian datasets but because there was little
variation in these densities (typically 16–32 gametocytes/L),
we considered it appropriate to present microscopic gameto-
cyte prevalence data only. Although the sampling interval in
the Tanzanian and Nigerian datasets was relatively large, this
may not guarantee independence of observations.28 There-
fore, multiple logistic regression models with GEEs were ini-
tially used to test the relation between P. falciparum game-
tocyte prevalence and the presence of P. falciparum and P.
malariae mixed infections in all data sets. Estimates were ad-
justed for potential confounding factors and a random effect
was included in the models to show correlations within per-
sons. If the addition of the random effect did not improve the
model, as was the case for data from Tanzania, outcomes of
conventional logistic regression models were presented.
RESULTS
Gametocytemia and mixed species infections after antima-
larial drug treatment. In Mbita, Kenya, 127 P. falciparum
mono-infections and 21 P. falciparum and P. malariae mixed
infections were treated with SP plus AQ. The presence of P.
malariae parasites was confirmed by P. malariae 18S riboso-
mal RNA QT-NASBA in all mixed species infections (21 of
21) and in none of the P. falciparum mono-infections (0 of 47)
tested. Complete 28-day follow-up data were available for 115
P. falciparum mono-infections and 20 mixed species infec-
P. FALCIPARUM GAMETOCYTEMIA IN MIXED INFECTIONS 443
tions. An adequate clinical response was observed in 87.0%
(100 of 115) of the P. falciparum mono-infections and 100%
(20 of 20) of the mixed species infections (P 0.13). Children
with mixed species infections were significantly older than
those with P. falciparum mono-infections (P  0.007; Table
1). Microscopic P. falciparum gametocyte prevalence was
non-significantly higher in mixed species infections (P 
0.26; Table 1).
Gametocyte prevalence by Pfs25 QT-NASBA was 91.1%
(41 of 45) in P. falciparum mono-infections at enrollment and
90.5% (19 of 21) in mixed species infections (P  0.93; Table
1). The Pfs25 QT-NASBA gametocyte prevalence at enroll-
ment was negatively associated with age (  −0.36, SE 
0.17, P  0.04) and showed a weak positive association with
microscopic asexual parasite density (  0.38, SE  0.35,
P  0.28). On the third day after the initiation of treatment,
Pfs25 QT-NASBA gametocyte prevalence was non-signifi-
cantly higher in mixed species infections (P  0.07) (Figure
1A) without any clear difference during the rest of follow-up.
When the entire period of follow-up was considered, there
was no statistically significant difference in the prevalence of
gametocytes by Pfs25 QT-NASBA between P. falciparum
mono-infections and mixed species infections (GEE  0.21,
SE  0.42, P  0.62), after adjustment for age and asexual
parasite density at enrollment. However, in Pfs25 QT-
NASBA gametocyte carriers, the Pfs25 QT-NASBA game-
tocyte density was consistently increased in mixed species in-
fections (Figure 1B). The geometric mean Pfs25 QT-NASBA
density was more than two-fold higher on the third day after
initiation of treatment in mixed species infections: 2.9 game-
tocytes/L (95% confidence interval [CI] = 0.7–12.4) for
P. falciparum mono-infections and 8.2 gametocytes/L (95%
CI  3.1–21.3) for mixed species infections (P  0.11). The
Pfs25 QT-NASBA gametocyte density throughout the study
period was significantly higher in mixed infections than in
mono-infections (GEE  0.38, SE  0.17, P  0.03) after
adjustment for age and microscopic P. falciparum asexual
parasite density at enrollment. Treatment outcome and the
presence of fever at enrollment did not confound this rela-
tionship.
The transmission potential during follow-up, quantified as
the AUC of Pfs25 QT-NASBA gametocyte density ver-
sus time, was significantly higher for mixed species infections
(P  0.02; Table 2). The number of sampling times when
gametocytes were detected by Pfs25 QT-NASBA was not
significantly different between the two groups (P 0.45), but
the geometric mean Pfs25 QT-NASBA gametocyte density in
Pfs25 QT-NASBA gametocyte-positive samples was higher in
mixed species infections (P  0.03; Table 2).
Gametocyte prevalence in mixed species infections in pre-
viously conducted studies. We analyzed three datasets on the
relationship between P. falciparum and P. malariae mixed
TABLE 1
Baseline characteristics of children with Plasmodium falciparum mono-infection or P. falciparum and P. malariae mixed infection*
Characteristic P. falciparum mono-infection P. falciparum and P. malariae mixed infection P
No. of children 127 21
Age, years, median (IQR) 2.6 (1.4–4.9) 4.4 (2.3–6.0) 0.007
Sex, % male (n/N) 52.8 (67/127) 52.4 (11/21) 0.98
Fever, % (n/N) 53.5 (68/127) 38.1 (8/21) 0.19
Hb, median (IQR) 9.3 (8.0–10.7) 10.4 (8.5–11.0) 0.11
P. malariae
Microscopic asexual parasite density, GM (IQR) – 1,419 (800–2,600) –
P. falciparum
Microscopic asexual parasite density, GM (IQR) 11,452 (5,040–31,679) 6,400 (3,143–16,858) 0.03
Microscopic gametocyte prevalence, % (n/N) 22.3 (27/121) 35.0 (7/20) 0.26
Pfs25 QT-NASBA gametocyte prevalence, % (n/N) 91.1% (41/45) 90.5% (19/21) 0.93
Pfs25 QT-NASBA gametocyte density, GM (IQR) 1.8 (0.3–9.7) 3.0 (0.8–11.7) 0.44
* IQR  interquartile range; Hb  hemoglobin concentration in g/dL; GM  geometric mean parasites density/L; QT-NASBA  quantitative nucleic acid sequence-based amplification.
FIGURE 1. Plasmodium falciparum gametocyte prevalence and
density determined by Pfs25 quantitative nucleic acid sequence-based
amplification (QT-NASBA) in P. falciparum mono-infections and
mixed infections with P. malariae. Shown are QT-NASBA gameto-
cyte prevalence (A) and density (B) for P. falciparum mono-
infections (closed triangles, broken line) and P. falciparum plus
P. malariae mixed infections (open squares, solid line). Bars indicate
the 95% confidence intervals.
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infection and the prevalence of P. falciparum gametocytes.
Prevalence data were available from multiple time points.
Data were presented for all time points combined; the fact
that multiple observations were derived from the same per-
sons was taken into account in the statistical analysis. There
was considerable variation in the strength of the association
between microscopic P. falciparum gametocyte prevalence
and mixed species infection (Table 3). We observed a bor-
derline significant increase in P. falciparum gametocyte
prevalence for mixed species infections in data from different
sites in north eastern Tanzania (odds ratio [OR]  2.15, 95%
CI  0.99–4.65) and this increase was statistically significant
for data from Kenya (OR  2.39, 95% CI 1.58–3.63), after
adjustment for age and concurrent microscopic asexual para-
site density. In the dataset from Nigeria, the effect varied
between different age groups. There was a borderline signifi-
cant lower microscopic P. falciparum gametocyte prevalence
in mixed species infections for persons less than 10 years of
age (OR  0.88, 95% CI 0.56–1.00), and there was a weak
and non-significant higher risk in older children after adjust-
ment for age and concurrent microscopic P. falciparum
asexual parasite density (OR  1.13, 95% CI 0.87–1.48).
DISCUSSION
In this study, we show that co-infection with P. malariae is
correlated with an increase in P. falciparum gametocytes. This
finding is consistent in three different studies from different
malaria-endemic areas, using both microscopy and molecular
methods; the effect was not apparent in a fourth study.
In Kenyan children with symptomatic malaria, we observed
a non-significantly higher microscopic P. falciparum gameto-
cyte prevalence prior to treatment. Although Pfs25 QT-
NASBA gametocyte prevalence was not significantly in-
creased, Pfs25 QT-NASBA gametocyte density was consis-
tently higher in mixed species infections throughout one
month of follow-up. This finding could not be explained by
differences in treatment efficacy, age, fever, or enrollment
parasite density. Kenyan children with mixed species infec-
tions were more likely to respond well to treatment, were
older, and had lower P. falciparum asexual parasite densities
at enrollment; all factors previously associated with lower
rather than higher gametocyte prevalence and density.26,29
In P. falciparum, most gametocytes that appear after treat-
ment are likely to have been committed to sexual stage de-
velopment prior to treatment. Gametocytes take 8–12 days to
develop30 and the peak in gametocyte prevalence and density
that is commonly seen after treatment is at least partly the
result of an efflux of these sequestered gametocytes.31 Al-
though a more pronounced release of gametocytes in the
presence of P. malariae co-infection could explain our find-
ings after antimalarial treatment, it seems more plausible that
mixed species infections have a higher commitment to pro-
duction of P. falciparum gametocytes that persist after treat-
ment, without a causative role for treatment as such. This
finding is also suggested by the non-significantly increased
microscopic gametocyte prevalence and Pfs25 QT-NASBA
gametocyte density in mixed species infections prior to treat-
ment.
Retrospective analysis of data from previously conducted
epidemiologic studies show a similar picture. In studies con-
ducted in Kenya and Tanzania, we observed a significantly
higher microscopic prevalence of P. falciparum gametocytes
in mixed species infections. Because microscopy underesti-
mates the total proportion of gametocyte carriers and only
detects relatively high gametocyte densities,19 these micro-
scopic findings can be interpreted as a higher prevalence of
high density gametocyte carriage in mixed species infections.
The Nigerian Garki study did not confirm the relationship
between P. falciparum gametocytemia and mixed species in-
fections. In contrast, there was a non-significantly lower P.
falciparum gametocyte prevalence associated with mixed spe-
cies infection in children less than 10 years of age,1 and there
was a weak and non-significant increased risk of P. falciparum
gametocyte carriage in older persons with mixed species in-
fections. This finding indicates that the relationship between
mixed species infections and gametocytemia may be different
under different endemicities. Despite this consideration, our
TABLE 2
Pfs25 QT-NASBA gametocyte carriage during follow-up for children with Plasmodium falciparum mono-infection or P. falciparum and P.
malariae mixed infection*
Characteristic P. falciparum mono-infection P. falciparum and P. malariae mixed infection P
Mean AUC of gametocyte density/L vs. time, (IQR) 0.9 (0.1–8.4) 5.5 (3.3–18.1) 0.02†
No. of sampling times when gametocytes were detected, % (n/N) 74.5 (158/212) 79.4 (81/102) 0.45†‡
GM gametocyte density/L on days when gametocytes were
detected (IQR) 1.9 (0.4–13.0) 4.0 (1.0–14.3) 0.03†‡
* QT-NASBA  quantitative nucleic acid sequence-based amplification; AUC  area under the curve; IQR  interquartile range; GM  geometric mean.
† Adjusted for log-transformed asexual parasite density at enrollment and age.
‡ Adjusted for correlations between observations from the same person.
TABLE 3
Re-examination of studies detecting Plasmodium falciparum gametocytes in mono-infections and P. falciparum plus P. malariae mixed infections*
Characteristic
Tanzania, 2005, all
age groups
Kenya, 2001, all
age groups
Nigeria, 1970–1971,
< 10 years
Nigeria, 1970–1971,
 10 years
P. falciparum mono-infection, % (n/N) 9.3 (187/2,007) 28.4 (342/1,206) 34.7 (1203/3,462) 9.6 (422/4,400)
P. falciparum and P. malariae mixed infection, % (n/N) 17.0 (9/53) 58.6 (68/116) 32.1 (604/1,880) 13.1 (81/619)
OR (95% CI) 2.15 (0.99–4.65)† 2.39 (1.58–3.63)† 0.88 (0.56–1.00)†‡ 1.13 (0.87–1.48)†‡
P value 0.05† < 0.001†‡ 0.05†‡ 0.37†‡
* OR  odds ratio; CI  confidence interval.
† Adjusted for concurrent log-transformed asexual P. falciparum parasite density and age in years.
‡ Adjusted for correlations between observations from the same individual. Data were derived from previously published studies that were conducted in Tanzania,24 Kenya,25 and Nigeria.26
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findings in three independent datasets strengthen our conclu-
sion that P. falciparum gametocyte production may be higher
in the presence of P. malariae parasites. This would confirm
observations from malariotherapy patients where co-infection
with P. malariae stimulates P. falciparum gametocyte produc-
tion.13 A possible influence in the other direction, i.e., a
change in P. malariae gametocytemia in mixed species infec-
tions, could not be determined. Plasmodium malariae game-
tocytes were not recorded in any of the studies discussed in
this report and a molecular tool to detect sexual stage para-
sites of other species than P. falciparum is currently unavail-
able.
Although three different studies show a similar relationship
between mixed species infections and P. falciparum gameto-
cytemia, our findings should be interpreted with caution. Ma-
laria-associated leukopenia may have impaired our estimate
of microscopic gametocyte density in Kenyan children with
symptomatic malaria, where a standard leukocyte concentra-
tion of 8,000 cells/L was assumed.32 Moreover, the extent of
leukopenia may differ between different plasmodium spe-
cies32 and could therefore confound relationships between
mixed species infections and microscopically estimated
asexual parasite or gametocyte densities. Leukocyte counts
are, however, unlikely to have influenced the major outcome
measures of this study, which were Pfs25 QT-NASBA game-
tocyte density and prevalence and microscopic gametocyte
prevalence. In addition, none of the conducted studies were
specifically designed to detect interactions between malaria
species. This would ideally require longitudinal studies in the
absence of antimalarial treatment. Our design hampers us to
draw conclusions on causality in the observed relations. Plas-
modium falciparum infections show parasitic waves that may
be followed by an increased gametocyte production.33 Simi-
larly, P. malariae parasite densities may increase when P.
falciparum densities decrease.34 This may result in a simulta-
neous increase in concentrations of P. malariae asexual para-
sites and P. falciparum gametocytes, making them more likely
to be detected by microscopy, without any causal relationship
between the two.
If there is a causal relationship between mixed species in-
fections and gametocyte production, it is likely to be mediated
by cross-species immune responses. Mixed genotype infec-
tions have been associated with higher transmission success
and higher gametocytemia in animal models.35 A similar phe-
nomenon may play a role in mixed species infections and may
indicate a response of parasites in terms of transmission po-
tential in the presence of a competitor. Although antibody-
mediated parasite immunity seems to be largely species and
strain-specific, it is likely that there is a certain degree of
cross-reactive immunity between species.36,37 There is evi-
dence for heterologous protective immunity for P. falciparum
induced by P. malariae9,37 and for cross-species regulation of
parasite densities.12,38,39 This cross-species immunity may
also influence malaria transmission.36 A higher infectivity of
parasites to mosquitoes in the presence of a different malaria
species was observed for simian malaria species40 and for
human P. vivax and P. falciparum in Aotus monkeys.41 Al-
though we did not determine immune responses, we hypoth-
esize that cross-reactive antibodies may play a role in explain-
ing our findings. Antibodies that are cross-reactive between
species may increase the immune stress experienced by P.
falciparum, thereby stimulating this species to invest in trans-
mission stages. The observation from the Garki dataset that
increased gametocyte prevalence is only observed in children
more than 10 years of age may be related to the development
of clinical immunity in this age group. Further analysis allow-
ing for the effects of transmission intensity of both P. falci-
parum and P. malariae is warranted but beyond the scope of
this report.
The relevance of our findings for malaria transmission de-
pends on prevalence of mixed species infections and influence
of an increase in gametocyte density on malaria transmission
potential. We have recently shown a positive association be-
tween gametocyte density and the proportion of infected
mosquitoes, including submicroscopic gametocyte densities.42
Thus, the higher densities of gametocytes (and the higher
prevalence of high density gametocyte carriage) in mixed spe-
cies infections are likely to result in a higher proportion of
infected mosquitoes. The infectiousness of gametocytes in
symptomatic Kenyan children was confirmed on day 14 after
the initiation of treatment, with 23 of 28 children with P.
falciparum mono-infections17 and 3 of 4 children with P. fal-
ciparum and P. malariae mixed infections infecting at least
one mosquito. The prevalence of mixed species infections in
a given population is highly variable. Plasmodium falciparum
and P. malariae mixed infections may account for 6% of the
P. falciparum malaria cases in western Kenya,43 but the
prevalence may be much higher in longitudinal studies2–4 or
in studies using species specific molecular detection tech-
niques.1,44 In our study, we found no sub-patent P. malariae
infections in children with apparent P. falciparum mono-
infections although a study from Mozambique found a two-
fold increase in the proportion of mixed species infections
using a polymerase chain reaction.1 The prevalence of P. ma-
lariae infections may further increase when P. falciparum-
specific control programs are implemented,2 such as current
vaccine trials.
In conclusion, our data suggest that the transmission po-
tential of P. falciparum is increased by co-infection with P.
malariae. Longitudinal studies are needed to confirm this re-
lationship, to identify possible mechanisms, and to determine
the duration and relevance of the potential increase in ma-
laria transmission that we observe. These longitudinal studies
should preferably use molecular tools to detect and quantify
the different stages of parasite species in the absence of ma-
laria treatment.
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